The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes…
EPI Data Slicer
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of T2D for each…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Type 2 Diabetes Mellitus patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of T2D comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of T2D for each…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…